WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition

Wang, RQ; Li, YL; Gao, JJ; Luan, YP

Gao, JJ (通讯作者),Qingdao Univ, Qingdao Med Coll, Sch Pharm, Dept Pharmacol, Qingdao, Shandong, Peoples R China.;Luan, YP (通讯作者),Qingdao Univ, Qingdao Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China.

DRUG DISCOVERIES AND THERAPEUTICS, 2022; 16 (6): 286

Abstract

Gemcitabine is widely used in the clinic as a first-line antitumor agent. However, intrinsic and acquired resistance hinders its wide clinical applica......

Full Text Link